注意欠陥多動性障害の世界市場（2023年～2032年）：市場シェア、規模、動向、業界分析、薬剤タイプ別、人口統計別、流通チャネル別、地域別、セグメント予測

世界の注意欠陥多動性障害の市場規模は、2032年までに321億4,000万米ドルに達すると予想されています。

当レポートでは、世界の注意欠陥多動性障害市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

• レポートについて
  • 調査目的
  • 市場範囲
  • 前提条件
• 利害関係者

第2章 エグゼクティブサマリー

• 市場のハイライト

第3章 調査手法

• 概要
  • データマイニング
• データ情報源
  • 一次情報源
  • 二次情報源

第4章 世界の注意欠陥多動性障害市場：洞察

• 業界のスナップショット
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターのファイブフォース分析
  • 供給企業の交渉力（中）
  • 新規参入者の脅威（低）
  • 買い手の交渉力（中）
  • 代替の脅威（中）
  • 既存企業間の競争（高）
• PESTLE分析
• 業界の動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界の注意欠陥多動性障害市場：薬剤タイプ別

• 主な調査結果
• イントロダクション
  • 薬剤タイプ別の世界市場（2019年～2032年）
• 刺激性
  • 刺激性別、地域別
  • アンフェタミン
  • メチルフェニデート
  • リスデキサンフェタミン
  • デクスメチルフェニデート
• 非刺激性
  • 非刺激性別、地域別
  • アトモキセチン
  • グアンファシン
  • クロニジン
  • その他

第6章 世界の注意欠陥多動性障害市場：流通チャネル別

• 主な調査結果
• イントロダクション
  • 流通チャネル別の世界市場（2019年～2032年）
• 小売薬局
  • 小売薬局別、地域別
• 病院薬局
  • 病院薬局別、地域別

第7章 世界の注意欠陥多動性障害市場：人口統計別

• 主な調査結果
• イントロダクション
  • 人口統計別の世界市場（2019年～2032年）
• 子供（2歳～17歳）
  • 子供（2歳～17歳）別、地域別
• 大人
  • 大人別、地域別

第8章 世界の注意欠陥多動性障害市場：地域別

• 主な調査結果
• イントロダクション
  • 注意欠陥多動性障害市場の評価：地域別（2019年～2032年）
• 北米
  • 薬剤タイプ別
  • 人口統計別
  • 流通チャネル別
  • 米国
  • カナダ
• 欧州
  • 薬剤タイプ別
  • 人口統計別
  • 流通チャネル別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
• アジア太平洋地域
  • 薬剤タイプ別
  • 人口統計別
  • 流通チャネル別
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
• 中東・アフリカ
  • 薬剤タイプ別
  • 人口統計別
  • 流通チャネル別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
• ラテンアメリカ
  • 薬剤タイプ別
  • 人口統計別
  • 流通チャネル別
  • メキシコ
  • ブラジル
  • アルゼンチン

第9章 競合情勢

• 拡張と買収の分析
  • 拡張
  • 買収
• パートナーシップ/コラボレーション/協定/展示会

第10章 企業プロファイル

• Adlon Therapeutics L.P
• Amnel Pharmaceuticals LLC
• Aytu Biopharma, Inc
• American Brivision（Holding）Corporation
• Cingulate Inc
• Eli Lilly And Company
• GSK plc
• Johnson & Johnson Services, Inc.
• Neos Therapeutics, Inc
• Novartis AG
• Noven Pharmaceuticals, Inc
• Otsuka Pharmaceutical Co., Ltd
• Purdue Pharma L.P
• RespireRx Pharmaceuticals Inc
• Supernus Pharmaceuticals, Inc
• Takeda Pharmaceutical Company Limited
• Tris Pharma, Inc

List of Tables

• Table 1 Global Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 2 Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 3 Global Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 4 Attention Deficit Hyperactivity Disorder Market Assessment, By Geography, 2019-2032 (USD Billion)
• Table 5 North America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 6 North America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 7 North America: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 8 U.S.: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 9 U.S.: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 10 U.S.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 11 Canada: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 12 Canada: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 13 Canada: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 14 Europe: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 15 Europe: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 16 Europe: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 17 UK: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 18 UK: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 19 UK: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 20 France: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 21 France: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 22 France: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 23 Germany: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 24 Germany: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 25 Germany: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 26 Italy: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 27 Italy: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 28 Italy: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 29 Spain: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 30 Spain: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 31 Spain: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 32 Netherlands: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 33 Netherlands: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 34 Netherlands: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 35 Russia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 36 Russia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 37 Russia: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 38 Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 39 Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 40 Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 41 China: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 42 China: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 43 China: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 44 India: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 45 India: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 46 India: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 47 Malaysia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 48 Malaysia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 49 Malaysia: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 50 Japan: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 51 Japan: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 52 Japan: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 53 Indonesia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 54 Indonesia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 55 Indonesia: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 56 South Korea: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 57 South Korea: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 58 South Korea: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 59 Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 60 Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 61 Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 62 Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 63 Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 64 Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 65 UAE: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 66 UAE: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 67 UAE: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 68 Israel: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 69 Israel: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 70 Israel: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 71 South Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 72 South Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 73 South Africa: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 74 Latin America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 75 Latin America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 76 Latin America: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 77 Mexico: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 78 Mexico: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 79 Mexico: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 80 Brazil: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 81 Brazil: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 82 Brazil: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• Table 83 Argentina: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• Table 84 Argentina: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 85 Argentina: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)

List of Figures

• Figure 1. Global Attention Deficit Hyperactivity Disorder Market, 2019-2032 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Distribution Channel
• Figure 7. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021 & 2030 (USD Billion)
• Figure 8. Market by Drug Type
• Figure 9. Global Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2021 & 2030 (USD Billion)
• Figure 10. Market by Demographics
• Figure 11. Global Attention Deficit Hyperactivity Disorder Market, by Demographics, 2021 & 2030 (USD Billion)
• Figure 12. Attention Deficit Hyperactivity Disorder Market Assessment, By Geography, 2019-2032 (USD Billion)
• Figure 13. Strategic Analysis - Attention Deficit Hyperactivity Disorder Market

The global attention deficit hyperactivity disorder market size is expected to reach USD 32.14 billion by 2032, according to a new study by Polaris Market Research. The report "Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, and Non-Stimulants); By Demographics; By Distribution Channel; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The expansion of the worldwide attention deficit hyperactivity disorder (ADHD) treatment market is anticipated to be fueled by prominent firms specializing in research & development for the treatment of the condition. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. released the phase 3 clinical trials evaluating the effectiveness, safety, and tolerability of oral centanafadin for the treatment of adults with ADHD. Along with investigating centanafadine's effects in young children with ADHD, the business also intends to consult with the US Food and Drug Administration about the following procedures.

Furthermore, according to a study published in February 2021 and titled "The incidence of adult attention-deficit hyperactivity disorder: A global critical appraisal and meta-analysis," the pervasiveness of persistent adult ADHD was 2.6%, and the incidence of symptomatic adult ADHD was 6.7%, transforming to 139.8 Mn & 366.3 Mn affected adults worldwide, in 2020. The market is therefore likely to grow throughout the forecast period due to the growing burden of ADHD and the rising need for its treatment.

Additionally, medicine FDA approvals for attention deficit hyperactivity disorder are rising which is boosting the market growth over the forecast period. For instance, in July 2021, Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII's prescription information was updated owing to FDA approval of a supplementary New Drug Application (sNDA), according to a statement from the Adlon Therapeutics.

Also, the establishment of a center of excellence to enhance diagnosis, treatment, and care in Southeast Asia will be supported by a collaboration between Siemens Healthcare HMI Group, which was established in February 2022. This collaboration advances the study and creation of brand-new ADHD medications in the Asia Pacific area. The market for treatments for ADHD has been adversely affected by the Covid-19 outbreak. involving the industries. Due to the fast urbanization and growing need for efficient use of space that already exists, the sector anticipates a lot of needs and demands following the pandemic.

Attention Deficit Hyperactivity Disorder Market Report Highlights

The hospital pharmacy segment is anticipated to grow at a high CAGR over the forecast period. As drug specialists, hospital pharmacists can help ADHD patients and their parents choose the right medications.

The adult segment accounted for largest revenue share due to the huge target population base and increased risk of acquiring focus hyperactivity disorder.

Asia-Pacific is expected to grow at a high CAGR over the projected period. The existence of major market participants and their strategic efforts to create and promote innovative patient-focused goods

The global players include Adlon Therapeutics, American Brivision, Cingulate Inc., Eli Lilly, Neos Therapeutics, Novartis AG, Noven Pharmaceuticals, Purdue Pharma, RespireRx Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical, and Tris Pharma.

Polaris Market Research has segmented the Attention Deficit Hyperactivity Disorder market report based on drug type, distribution channel, demographics, and region:

Attention Deficit Hyperactivity Disorder, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

Stimulants

Amphetamine

Methylphenidate

Lisdexamfetamine

Dexmethylphenidate

Non-stimulants

Atomoxetine

Guanfacine

Clonidine

Others

Attention Deficit Hyperactivity Disorder, Demographics Outlook (Revenue - USD Billion, 2019 - 2032)

Children (2 to 17 years of age)

Adults

Attention Deficit Hyperactivity Disorder, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Retail Pharmacy

Hospital Pharmacy

Attention Deficit Hyperactivity Disorder, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Attention Deficit Hyperactivity Disorder Market Insights

• 4.1. Attention Deficit Hyperactivity Disorder - Industry Snapshot
• 4.2. Attention Deficit Hyperactivity Disorder Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Awareness About ADHD Among Physicians and Patients
    • 4.2.1.2. Increasing Prevalence of ADHD
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Low Availability of Non-stimulant ADHD Drugs
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Attention Deficit Hyperactivity Disorder Market Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Attention Deficit Hyperactivity Disorder Market, by Drug Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
• 5.3. Stimulants
  • 5.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Stimulants, by Region, 2019-2032 (USD Billion)
  • 5.3.2. Amphetamine
    • 5.3.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Amphetamine, by Region, 2019-2032 (USD Billion)
  • 5.3.3. Methylphenidate
    • 5.3.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Methylphenidate, by Region, 2019-2032 (USD Billion)
  • 5.3.4. Lisdexamfetamine
    • 5.3.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Lisdexamfetamine, by Region, 2019-2032 (USD Billion)
  • 5.3.5. Dexmethylphenidate
    • 5.3.5.1. Global Attention Deficit Hyperactivity Disorder Market, by Dexmethylphenidate, by Region, 2019-2032 (USD Billion)
• 5.4. Non-stimulants
  • 5.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Non-stimulants, by Region, 2019-2032 (USD Billion)
  • 5.4.2. Atomoxetine
    • 5.4.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Atomoxetine, by Region, 2019-2032 (USD Billion)
  • 5.4.3. Guanfacine
    • 5.4.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Guanfacine, by Region, 2019-2032 (USD Billion)
  • 5.4.4. Clonidine
    • 5.4.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Clonidine, by Region, 2019-2032 (USD Billion)
  • 5.4.5. Other
    • 5.4.5.1. Global Attention Deficit Hyperactivity Disorder Market, by Other, by Region, 2019-2032 (USD Billion)

6. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• 6.3. Retail Pharmacy
  • 6.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
• 6.4. Hospital Pharmacy
  • 6.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)

7. Global Attention Deficit Hyperactivity Disorder Market, by Demographics

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
• 7.3. Children (2 to 17 years of age)
  • 7.3.1. Global Attention Deficit Hyperactivity Disorder Market, by Children (2 to 17 years of age), by Region, 2019-2032 (USD Billion)
• 7.4. Adults
  • 7.4.1. Global Attention Deficit Hyperactivity Disorder Market, by Adults, by Region, 2019-2032 (USD Billion)

8. Global Attention Deficit Hyperactivity Disorder Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Attention Deficit Hyperactivity Disorder Market Assessment, By Geography, 2019-2032 (USD Billion)
• 8.3. Attention Deficit Hyperactivity Disorder Market - North America
  • 8.3.1. North America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.3.2. North America: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
  • 8.3.3. North America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3.4. Attention Deficit Hyperactivity Disorder Market - U.S.
    • 8.3.4.1. U.S.: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4.2. U.S.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.3.4.3. U.S.: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3.5. Attention Deficit Hyperactivity Disorder Market - Canada
    • 8.3.5.1. Canada: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5.2. Canada.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.3.5.3. Canada: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.4. Attention Deficit Hyperactivity Disorder Market - Europe
  • 8.4.1. Europe: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4.2. Europe.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
  • 8.4.3. Europe: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.4. Attention Deficit Hyperactivity Disorder Market - UK
    • 8.4.4.1. UK: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4.2. UK.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.4.3. UK: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.5. Attention Deficit Hyperactivity Disorder Market - France
    • 8.4.5.1. France: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5.2. France.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.5.3. France: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.6. Attention Deficit Hyperactivity Disorder Market - Germany
    • 8.4.6.1. Germany: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6.2. Germany.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.6.3. Germany: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.7. Attention Deficit Hyperactivity Disorder Market - Italy
    • 8.4.7.1. Italy: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7.2. Italy.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.7.3. Italy: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.8. Attention Deficit Hyperactivity Disorder Market - Spain
    • 8.4.8.1. Spain: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8.2. Spain.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.8.3. Spain: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.9. Attention Deficit Hyperactivity Disorder Market - Netherlands
    • 8.4.9.1. Netherlands: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9.2. Netherlands.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.9.3. Netherlands: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4.10. Attention Deficit Hyperactivity Disorder Market - Russia
    • 8.4.10.1. Russia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10.2. Russia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.4.10.3. Russia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.5. Attention Deficit Hyperactivity Disorder Market - Asia Pacific
  • 8.5.1. Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5.2. Asia Pacific.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
  • 8.5.3. Asia Pacific: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.4. Attention Deficit Hyperactivity Disorder Market - China
    • 8.5.4.1. China: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4.2. China.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.4.3. China: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.5. Attention Deficit Hyperactivity Disorder Market - India
    • 8.5.5.1. India: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5.2. India.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.5.3. India: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.6. Attention Deficit Hyperactivity Disorder Market - Malaysia
    • 8.5.6.1. Malaysia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6.2. Malaysia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.6.3. Malaysia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.7. Attention Deficit Hyperactivity Disorder Market - Japan
    • 8.5.7.1. Japan: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7.2. Japan.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.7.3. Japan: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.8. Attention Deficit Hyperactivity Disorder Market - Indonesia
    • 8.5.8.1. Indonesia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8.2. Indonesia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.8.3. Indonesia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5.9. Attention Deficit Hyperactivity Disorder Market - South Korea
    • 8.5.9.1. South Korea: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9.2. South Korea.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.5.9.3. South Korea: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.6. Attention Deficit Hyperactivity Disorder Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6.2. Middle East & Africa.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
  • 8.6.3. Middle East & Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.6.4. Attention Deficit Hyperactivity Disorder Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4.2. Saudi Arabia.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.6.5. Attention Deficit Hyperactivity Disorder Market - UAE
    • 8.6.5.1. UAE: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5.2. UAE.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.6.5.3. UAE: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.6.6. Attention Deficit Hyperactivity Disorder Market - Israel
    • 8.6.6.1. Israel: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6.2. Israel.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.6.6.3. Israel: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.6.7. Attention Deficit Hyperactivity Disorder Market - South Africa
    • 8.6.7.1. South Africa: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7.2. South Africa.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.6.7.3. South Africa: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.7. Attention Deficit Hyperactivity Disorder Market - Latin America
  • 8.7.1. Latin America: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7.2. Latin America.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
  • 8.7.3. Latin America: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.7.4. Attention Deficit Hyperactivity Disorder Market - Mexico
    • 8.7.4.1. Mexico: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4.2. Mexico.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.7.4.3. Mexico: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.7.5. Attention Deficit Hyperactivity Disorder Market - Brazil
    • 8.7.5.1. Brazil: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5.2. Brazil.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.7.5.3. Brazil: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.7.6. Attention Deficit Hyperactivity Disorder Market - Argentina
    • 8.7.6.1. Argentina: Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6.2. Argentina.: Attention Deficit Hyperactivity Disorder Market, by Demographics, 2019-2032 (USD Billion)
    • 8.7.6.3. Argentina: Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2019-2032 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Adlon Therapeutics L.P
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Amnel Pharmaceuticals LLC
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Aytu Biopharma, Inc
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. American Brivision (Holding) Corporation
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Cingulate Inc
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Eli Lilly And Company
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. GSK plc
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Johnson & Johnson Services, Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Neos Therapeutics, Inc
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Novartis AG
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Noven Pharmaceuticals, Inc
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Otsuka Pharmaceutical Co., Ltd
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Purdue Pharma L.P
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. RespireRx Pharmaceuticals Inc
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Supernus Pharmaceuticals, Inc
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development
• 10.16. Takeda Pharmaceutical Company Limited
  • 10.16.1. Company Overview
  • 10.16.2. Financial Performance
  • 10.16.3. Product Benchmarking
  • 10.16.4. Recent Development
• 10.17. Tris Pharma, Inc
  • 10.17.1. Company Overview
  • 10.17.2. Financial Performance
  • 10.17.3. Product Benchmarking
  • 10.17.4. Recent Development